Wikipedia

Draft:Every Cure



Every Cure
Founded2022
FoundersDavid Fajgenbaum, Grant Mitchell, Tracey Sikora
Type501(c)(3) nonprofit organization
HeadquartersNew York, New York
President
Dr. David Fajgenbaum
Websiteeverycure.org

Every Cure is an American nonprofit organization dedicated to identifying and advancing repurposed drugs to alleviate suffering for millions of people globally who are battling diseases with no approved treatments.[1] Co-founded in 2022 by physician-scientist David Fajgenbaum, Grant Mitchell, and Tracey Sikora, Every Cure uses artificial intelligence to identify matches between FDA-approved drugs and known diseases, pinpointing the most promising opportunities for drug repurposing and aiming to deliver treatments to patients in months rather than decades, at a fraction of the cost of new drug development.[2]

History

edit

In 2010, David Fajgenbaum, a third-year medical student, became critically ill with Castleman disease, a rare inflammatory disorder.[3] He spent months hospitalized in critical condition and nearly died five times. Doctors told him there were no more options for his disease, and developing a brand new treatment—which would require billions of research dollars and 10–15 years—was not feasible. Repurposing an existing drug was his only hope.[3] Repurposing existing drugs is possible because many diseases share underlying biological mechanisms, and many drugs have multiple mechanisms of action.[4] Fajgenbaum launched an initiative to find treatments to save his life and the lives of others with Castleman disease. He and his team discovered an overactive pathway in his blood and tested a 25-year-old drug called Sirolimus, approved as an immunosuppressant after kidney transplants but never previously used for Castleman disease, to block that pathway.[3] As a result of this repurposed drug, he has been in remission for more than 11 years. During this time, Fajgenbaum has gone on to advance multiple additional repurposed drugs for more diseases.[2]

Inspired by this success, Fajgenbaum co-founded Every Cure to scale drug repurposing efforts and ensure patients aren’t left waiting when potential treatments are sitting underutilized on pharmacy shelves. Since its launch, Every Cure has advanced multiple repurposed drugs for rare and under-treated diseases and aims to unlock treatments for 15 to 25 diseases by 2030.[2]

Mission and Vision

edit

Every Cure’s mission is “to save and improve lives by repurposing drugs.” Its vision is to create a world where every drug is used to treat every disease it can. The organization focuses on impact-driven drug repurposing, which involves systematically looking across all possible repurposed treatments to find the greatest opportunities to impact patients' lives. This data-driven approach maximizes the likelihood of success and the impact that can be made per dollar spent.[2]

Approach

edit

Every Cure employs a novel methodology known as computational pharmacophenomics[5] to analyze the world’s biomedical knowledge and identify promising opportunities for drug repurposing across all FDA-approved drugs and recognized diseases. Unlike traditional drug repurposing, which begins with a specific drug or disease, Every Cure’s approach evaluates over 4,000 approved drugs and over 18,000 recognized diseases simultaneously, allowing the organization to prioritize opportunities with the highest potential impact.[6]

The organization uses multiple AI–driven methods to generate a ranked list of repurposing opportunities:[7]

  • Knowledge graph-based approaches: Every Cure integrates over 100 biomedical datasets, including drug mechanisms, gene interactions, and disease pathways, into an AI-readable map of human biology. Predictive models use this knowledge graph to identify potential connections between drugs and diseases.
  • Large language model-based approaches: Advanced language models are used to replicate the reasoning of medical experts, evaluate evidence, and identify drugs that could treat specific diseases.
  • Real-world evidence-based approaches: Medical data, including prescriptions and electronic health records, are analyzed to detect associations between drugs and new disease indications that might not be apparent in conventional research.

Human experts review and prioritize the top-ranked opportunities, focusing on diseases with the greatest unmet medical need. For each promising opportunity, rounds of review and discussion occur to ensure a thorough understanding of the patient journey, the drug’s mechanism and usage, existing evidence, and how Every Cure could facilitate access.[7]

Every Cure collaborates with clinical research organizations, academic labs, and patient advocacy groups to generate the necessary preclinical and clinical evidence. The organization also works to maximize patient access by assisting with regulatory approval, updating treatment guidelines, educating clinicians, and conducting outreach campaigns. The goal is to ensure that validated repurposed treatments reach as many patients as possible.[7]

Recognition

edit

Every Cure has been featured in media outlets including The New York Times, CBS Evening News, The Wall Street Journal, Good Morning America, The New Yorker, and USA Today.[8][9][10][11][12][13]

Awards include TIME100 Health,[14] TED Audacious Project recognition,[15] the Newsweek AI Impact Award,[16] and PA BIO “Emerging Company of the Year.”[17]

References

edit
  1. ^ "Every Cure". MIT Solve. Retrieved August 27, 2025.
  2. ^ a b c d "About". Every Cure. Retrieved August 27, 2025.
  3. ^ a b c Fajgenbaum, David (2019). Chasing My Cure: A Doctor's Race to Turn Hope into Action. Ballantine Books. ISBN 1524799610.
  4. ^ "Systematic computational pharmacophenomics for drug repurposing". bioRxiv. June 13, 2025. doi:10.1101/2025.06.13.659527.
  5. ^ "Drug repurposing: how AI can accelerate treatments for neglected diseases". The Lancet Healthy Longevity. 5 (12). 2024.
  6. ^ "Drug Repurposing: How Every Cure's AI Platform Unlocks Treatments". HealthTech Remedy. 2024. Retrieved August 27, 2025.
  7. ^ a b c "Our Work". Every Cure. Retrieved August 27, 2025.
  8. ^ "AI and drug repurposing". The New York Times. March 20, 2025.
  9. ^ "Autism, Leucovorin, and medicine". CBS Evening News. 2025.
  10. ^ "This Doctor Found His Own Miracle Drug—Now He Wants to Do It for Others". The Wall Street Journal. 2025.
  11. ^ "Interview with David Fajgenbaum". Good Morning America. 2025.
  12. ^ "Can AI find cures for untreatable diseases using drugs we already have?". The New Yorker. 2025.
  13. ^ "Every Cure and Clinton Global Initiative". USA Today. September 18, 2022.
  14. ^ "TIME100 Health 2025". TIME. 2025.
  15. ^ "Every Cure Receives Five-Year $60 Million Commitment". Every Cure. 2023.
  16. ^ "AI Impact Awards 2025". Newsweek. 2025.
  17. ^ "PA BIO Awards". PA BIO. 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Every_Cure&oldid=1309045803"